Agios Pharmaceuticals Stock (NASDAQ:AGIO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$41.96

52W Range

$20.96 - $62.58

50D Avg

$49.73

200D Avg

$42.08

Market Cap

$2.23B

Avg Vol (3M)

$760.82K

Beta

0.75

Div Yield

-

AGIO Company Profile


Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

383

IPO Date

Jul 24, 2013

Website

AGIO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 20
Royalty-$2.50M$10.26M
Product$26.82M$11.74M$121.09M
Collaboration Revenue, Related Party--$68.27M
Commercialization Activity--$3.93M
Committee Participation---
Development Activities---
Research Services--$64.35M

Fiscal year ends in Dec 23 | Currency in USD

AGIO Financial Summary


Dec 23Dec 22Dec 21
Revenue$26.82M$14.24M-
Operating Income$-391.49M$-389.05M$-378.42M
Net Income$-352.09M$-74.56M$1.60B
EBITDA$-384.86M$-526.75M$-385.06M
Basic EPS$-6.33$-1.36$26.55
Diluted EPS$-6.33$-1.36$26.55

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 31, 24 | 2:16 PM
Q2 24Aug 01, 24 | 12:11 PM
Q1 24May 02, 24 | 4:32 PM

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc.
KALVKalVista Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
ANABAnaptysBio, Inc.
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
COGTCogent Biosciences, Inc.
BDTXBlack Diamond Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
NRIXNurix Therapeutics, Inc.
KYMRKymera Therapeutics, Inc.
ARVNArvinas, Inc.
IDYAIDEAYA Biosciences, Inc.
MREOMereo BioPharma Group plc
KROSKeros Therapeutics, Inc.
MGTXMeiraGTx Holdings plc
BMRNBioMarin Pharmaceutical Inc.
CCCCC4 Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
MRSNMersana Therapeutics, Inc.